Navigation Links
New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
Date:5/9/2008

- Fifth International Phase III Study Shows Positive Results with X-ray

Data -

NUTLEY, N.J., May 9 /PRNewswire/ -- Roche today announced one-year results from a new two-year Phase III study showing that ACTEMRA(TM) (tocilizumab) can significantly inhibit progression of structural damage to joints in patients with rheumatoid arthritis (RA), a critical measure of effectiveness of an RA treatment. The study also demonstrated that ACTEMRA reduces disease signs and symptoms at one year. The LITHE study is the fifth international Phase III ACTEMRA trial to successfully meet its primary endpoints in patients with moderate to severe RA.

The one-year data from LITHE (TociLIzumab Safety and THE Prevention of Structural Joint Damage) trial showed that a greater proportion of patients treated with ACTEMRA (4 mg/kg or 8 mg/kg) plus methotrexate versus placebo plus methotrexate over 52 weeks achieved a significant reduction in the progression of structural joint damage, which is critical to RA patients because joint damage leads to disability. The study analysis included 1,196 patients from 137 trial sites in 15 countries. Twenty-eight percent of the patients were from the United States.

ACTEMRA was generally well tolerated; the most common adverse events reported more frequently in the ACTEMRA arm of the LITHE trial were upper respiratory tract infections, nasopharyngitis, hypertension, headache and an increase in transaminases.

"At one year, the results from the LITHE trial clearly demonstrate that ACTEMRA could be an effective component in the battle against the long-term debilitating effects of RA, including joint damage and loss of physical function," said Lars Birgerson, M.D., Ph.D., Global Head Medical Affairs, Roche. "The ACTEMRA clinical development program was designed to establish ACTEMRA as a first-line biologic in the treatment of RA. When you consider that this is the fifth consecutive successful
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... , April 27, 2015 Harwood Feffer ... the board of directors of Aerie Pharmaceuticals, Inc. ("Aerie" ... the board has breached its fiduciary duties to shareholders. ... a press release announcing results from its first Phase ... press release disclosed that in the trial, Rhopressa failed ...
(Date:4/27/2015)... Research and Markets ( ... "Endoscopy Global Market - Forecast to 2020" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ,The global endoscopy market ... 2019 growing at around 7.0% CAGR from 2014 ... growth are aging population, increase in cancer, diabetes, ...
(Date:4/27/2015)... , April 27, 2015 Vermillion, ... on gynecologic disease, announced today it will ... the market close on Monday, May 11, ... and webcast at 4:30pm Eastern.Conference Call & ... Eastern/1:30pm Pacific Domestic: , 888-556-4997International: , 719-457-2628Conference ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Aerie Pharmaceuticals, Inc. 2Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 2Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 3
(Date:4/27/2015)... 2015 The Doctors on Liens ... of personal injury attorneys with the best doctors working on ... steady growth throughout their history and that trend continues with ... and his team in the Tujunga / Sunland ... massage therapist, patients can find comprehensive care and detailed documentation ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 TayganPoint ... is proud to announce their sponsorship of Girls ... Counties. Girls on the Run is a ... through eighth grade. The program is delivered through ... uplifting workouts aimed to develop the whole girl ...
(Date:4/27/2015)... Ticket Down is a reputable source for ... Music Theatre and the Isleta Amphitheater. , ... area can celebrate because their favorite performer will be ... will be performing alongside legendary performers, Huey Lewis and ... the summer and fall months of 2015 are in ...
(Date:4/27/2015)... April 27, 2015 The Mount Sinai ... seamless referral process for the Health System’s care providers. ... failure or diabetes, for instance, may have more than ... coordinate with many other care providers. With medical practices ... thousands of patients each year, the need for an ...
(Date:4/27/2015)... Scooter Direct is now offering Pride ... price of only $929.00, marked down from the MSRP ... is known for offering quality mobility solutions to its ... wheel chairs, lift chairs, and their accessories at unbeatable ... of Go Go Traveller Elite, a senior store manager ...
Breaking Medicine News(10 mins):Health News:Prominent Doctors with Distinguished Backgrounds Join Doctors on Liens in Tujunga 2Health News:TayganPoint Consulting Group Announces Sponsorship of Girls on the Run 2Health News:Cheap Jimmy Buffett Tickets at Alpine Valley Music Theatre in Elkhorn, WI and at Isleta Amphitheater in Albuquerque, NM Now on Sale at TicketDown.com 2Health News:Mount Sinai Launches System for Faster Referrals 2Health News:Mount Sinai Launches System for Faster Referrals 3Health News:Scooter Direct Offering Pride Go Go Traveller Elite 3-Wheel Scooter At Discounted Price 2Health News:Scooter Direct Offering Pride Go Go Traveller Elite 3-Wheel Scooter At Discounted Price 3
... 31 XStor Medical Systems, a,privately held ... Imaging,Platform for advanced clinical applications and collaborative ... that facilitate participating,hospitals, clinics, and healthcare systems ... physician groups, and patients. The,XStor Imaging Platform ...
... Watson Pharmaceuticals, Inc. (NYSE: WPI ... pharmaceuticals, today announced that its subsidiary, Watson Laboratories, ... Food and Drug Administration to market its over-the-counter ... the 2 mg and 4 mg strengths.Nicotine Polacrilex ...
... often take gives them only a temporary fix, with tumors ... researchers at Johns Hopkins have discovered critical differences in the ... longer respond to this therapy. The findings, reported in the ... to a way to track disease progression, as well as ...
... BEIJING, Dec. 31 /PRNewswire-Asia-FirstCall/ -- China Medical ... ), a leading China-based medical device,company that ... today announced that the Company has completed ... Focused Ultrasound tumor therapy system,business (the "HIFU ...
... Medical Innovations, Inc. (Amex: IMA ), a ... solutions, announced today that it will attend the upcoming ... 15, 2009 at the Westin St. Francis Hotel in ... Jon Russell, Vice President, Finance, will attend. Mr. ...
... Cisplatin and Oxaliplatin Ototoxicity , More cisplatin enters ... The difference may explain why cisplatin treatment in humans ... , The amount of cisplatin a patient can tolerate ... drug, referred to as ototoxicity. Oxaliplatin is not frequently ...
Cached Medicine News:Health News:XStor Medical Systems Announces the Release of its Imaging Platform for Connectivity Between Healthcare Enterprises 2Health News:Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum 2Health News:Why prostate cancer patients fail hormone deprivation therapy 2Health News:China Medical Technologies Announces the Completion of the Sale of its HIFU Business 2Health News:China Medical Technologies Announces the Completion of the Sale of its HIFU Business 3Health News:China Medical Technologies Announces the Completion of the Sale of its HIFU Business 4Health News:China Medical Technologies Announces the Completion of the Sale of its HIFU Business 5Health News:Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 13, 2009 2Health News:Also in the Dec. 30 JNCI 2Health News:Also in the Dec. 30 JNCI 3
Micro-mini fiber optic light....
Xenon technology achieves a higher efficiency than halogen light sources. Consequently they provide more light....
International version of the Twin Beam, it is BSI-, IEC-, CE- approved....
Cold light source single outlet....
Medicine Products: